The Prognostic Value of Undetectable Highly Sensitive Cardiac Troponin I in Patients With Acute Pulmonary Embolism

Value of Cardiac Troponin and sPESI in Treatment of Pulmonary Thromboembolism at Outpatient Setting

“…A retrospective study by Hakemi et al found negative troponin levels in 137 of the 298 patients (49 %), and no mortality occurred in these patients. However, mortality was observed in one patient with low-risk sPESI and a negative troponin value (1.9 %) [17].…”

The diagnostic value of serum copeptin levels in an acute pulmonary embolism

“…In addition to evaluation of RVD by 2-dimensional (2D) transthoracic echocardiography (TTE), the use of inexpensive, easy-to-use and readily available measurements of biomarkers may be beneficial. Some proven efficacy biomarkers such as D-dimer, B-type natriuretic peptide (BNP), and troponin I are used in the diagnosis and risk stratification of APE [6][7][8][9].…”

Creatinine kinase isoenzyme–MB: A simple prognostic biomarker in patients with pulmonary embolism treated with thrombolytic therapy

“…Previous studies have showed that cTnT and cTnI are independent predictors of in-hospital and long-term mortality due to PE [10,[22][23][24][25][26]. The present study is the first to evaluate the relationship between admission CK-MB levels and in-hospital and long-term clinical outcomes in PE patients treated with t-PA. We showed that a cut-off CK-MB value of 31.5 U/l was ideal for predicting unfavourable in-hospital clinical outcomes.…”

“…All of these mechanisms result in RV ischemia and myocardial injury [1][2][3][4][5]. Different biomarkers, such as BNP, NT-pro BNP, cTnI or cTnT, and h-FABP, have been used to detect myocardial injury and RV dysfunction [1,[7][8][9][10][11][12]. In a meta-analysis, Klok et al [17] examined BNP and NT-proBNP levels in 1132 PE patients and found that elevated BNP and NT-pro BNP levels were strongly correlated with RV dysfunction and in-hospital and 30-day mortality.…”

“…RV dysfunction, an important predictor of mortality in PE cases, may be determined by imaging methods (computed tomography [CT], echocardiography) or laboratory markers such as brain natriuretic peptide (BNP), N-terminal (NT)-pro BNP, cardiac troponin I (cTnI) or T (cTnT), and heart-type fatty acid-binding protein (h-FABP) [1,[7][8][9][10][11][12]. Creatinine kinase isoenzyme MB (CK-MB) is an important biomarker for detecting myocardial injury [13].…”